<DOC>
	<DOCNO>NCT02607722</DOCNO>
	<brief_summary>This non-interventional study base new data collection gather real-world information ( i.e. , data routine medical practice ) safety effectiveness Ofev® Capsules treatment . The study consist baseline visit follow-up visit Week 4 , 13 , 26 , 39 , 52 , 65 , 78 , 91 104 patient newly initiate Ofev® Capsules . The patient follow discontinuation Ofev® Capsules treatment . As observational study , specific treatment mandate withheld patient . The choice maintenance treatment IPF must accord regular medical practice discretion physician ( i.e. , randomise assignment patient treatment perform ) . All patient administrate Ofev® Capsules launch site contract sponsor register . The Case Report Forms ( CRFs ) 1000 patient collect . However patient registration continue approval condition remove . Patients participate subsequent follow-up undergo regular observation . These observation report approximately Week 4 , 13 , 26 , 39 , 52 , 65 , 78 , 91 104 since initiation Ofev® Capsules long continue receive treatment . Patients follow longer report discontinued Ofev® Capsules treatment .</brief_summary>
	<brief_title>All-Case Surveillance Ofev Patients With IPF Japan</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Essentially , patient diagnose IPF base upon recent American Thoracic Society ( ATS ) , European Respiratory Society ( ERS ) , Japanese Respiratory Society ( JRS ) , Latin American Thoracic Association ( ALAT ) guideline .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>